Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study

BMC Pulmonary Medicine

Table 1 Patient characteristics at baseline

Characteristic	Full analysis set (n = 300)	Switched patients (n = 84)^a	Treatment-naïve patients (n = 216)
Sex, n (%)
Female	185 (62)	55 (65)	130 (60)
Male	115 (38)	29 (35)	86 (40)
Age (mean ± SD), years	63.9 ± 12.5	65.5 ± 11.6	63.3 ± 12.7
Type of CTEPH, n (%)
Inoperable	216 (72)	64 (76)	152 (70)
Persistent/recurrent	84 (28)	20 (24)	64 (30)
WHO FC, n (%)
I	5 (2)	0	5 (2)
II	112 (37)	31 (37)	81 (38)
III	175 (58)	51 (61)	124 (57)
IV	8 (3)	2 (2)	6 (3)
6MWD (mean ± SD), m	374 ± 117^b	389 ± 87^c	369 ± 125^d

6MWD 6-min walking distance, CTEPH chronic thromboembolic pulmonary hypertension, ERA endothelin receptor antagonist, PDE5 phosphodiesterase type 5, SD standard deviation, WHO FC World Health Organization functional class
^aPatients who previously received an ERA, prostacyclin, and/or PDE5 inhibitor, and who stopped this treatment before starting riociguat
^b n = 213; last observed value prior to start of study treatment
^c n = 52
^d n = 161

ISSN: 1471-2466